Myeloma : Pathology, Diagnosis, and Treatment
Myeloma is the second-most common hematologic cancer, accounting for approximately 1 percent of all cancers and 2 percent of all deaths from cancer. In recent years there have been major and significant advances in the diagnosis, imaging, molecular pathogenesis, and therapy of myeloma. This book describes these advances in a single, practical volume, placing them in the context of daily clinical practice. Different myeloma subtypes are discussed in individual chapters, integrating etiology, pathogenesis, molecular pathology, histology, and therapy in a single place for each condition. The book begins by discussing epidemiology, imaging techniques, pathogenesis, and other general considerations. Conditions covered in detail include multiple myeloma, POEMS syndrome, Castleman's syndrome, Waldenstrom's macroglobulinemia, amyloidosis and MGUS. Featuring color illustrations, and written and edited by leading authorities in the field, Myeloma provides readers with the information they need to diagnose and manage these complex disorders.
- Hardback | 304 pages
- 197 x 252 x 18mm | 860g
- 13 Jan 2014
- CAMBRIDGE UNIVERSITY PRESS
- Cambridge, United Kingdom
- 36 Tables, black and white; 29 Halftones, unspecified; 17 Halftones, color; 12 Line drawings, unspecified; 25 Line drawings, color
Table of contents
Preface; Part I. Overview of Myeloma: 1. Epidemiology of myeloma Eve Roman and Alexandra G. Smith; 2. Diagnosis and immunophenotyping of myeloma Roger Owen; 3. Imaging of myeloma Nicola Mulholland and Ming Wan; Part II. Biological Basis for Targeted Therapies in Myeloma: 4. Cell cycle regulation and myeloma precursor cells John Quinn and Kwee L. Yong; 5. The genetic and epigenetic mechanisms underlying the behaviour of myeloma Martin F. Kaiser, Kevin D. Boyd and Gareth J. Morgan; 6. The myeloma bone marrow environment and survival signaling Kwee L. Yong, John Quinn and Asim Khwaja; 7. Immune dysfunction in multiple myeloma Guy Pratt and Paul Moss; 8. Myeloma bone disease: pathogenesis of bone destruction and therapeutic strategies Andrew Chantry and Neil Rabin; 9. Principles of pathway directed therapy for myeloma Yu-Tzu Tai and Kenneth C. Anderson; Part III. Myeloma: Clinical Entities: 10. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma Efstathios Kastritis and Meletios A. Dimopoulos; 11. Multiple myeloma: management of de novo disease T. Guglielmelli, P. Sonneveld, A. Broyl and Antonio Palumbo; 12. Treatment of relapsed/refractory myeloma Matthew J. Streetly, Jacob Laubach, Paul Richardson and Stephen A. Schey; 13. Solitary bone and extramedullary plasmacytoma Shirley D'Sa; 14. Amyloidosis Ashutosh D. Wechalekar, Simon W. Dubrey and Raymond L. Comenzo; 15. Waldenstrom's macroglobulinemia/lymphoplasmocytic lymphoma Steven P. Treon and Giampaolo Merlini; 16. Castleman's disease Karthik Ramasamy; 17. POEMS syndrome and paraproteinaemic syndromes: management and follow-up Angela Dispenzieri and Suzanne R. Hayman; Part IV. Supportive Therapies: 18. Treatment of emergent peripheral neuropathy and plasma cell disorders Charise Gleason, Melanie Watson and Sagar Lonial; 19. Management of renal failure in multiple myeloma Aneel Paulus, Pooja Advani, Nabeel Aslam and Asher Alban Chanan-Khan; 20. The management of infection in myeloma Christopher P. Conlon; Index.
About Stephen A. Schey
Stephen A. Schey is Professor of Plasma Cell Dyscrasias, King's College London, and a Consultant Haematologist at King's College Hospital NHS Foundation Trust, London. Kwee L. Yong is Professor of Clinical Haematology, University College London, and a Consultant Haematologist at University College London Hospitals, London. Robert Marcus is a Consultant Haematologist at King's College Hospital NHS Foundation Trust, London. Kenneth C. Anderson is Kraft Family Professor of Medicine, Harvard Medical School, and Medical Director, Kraft Family Blood Donor Center, Dana-Faber Cancer Institute, Boston.